VIDAC PHARMA HOLDING PLC
Commented by André Will-Laudien on March 25th, 2026 | 09:35 CET
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer
The conflicts in the Middle East continue. With the first talks between the US and Iran, the stock markets made a lightning-fast upward adjustment. As a result, the German benchmark index DAX 40 gained a full 1,600 points within just 10 minutes at the start of the week. However, it was unable to hold that level, falling back to 22,600 points yesterday. The question now is whether the parties to the conflict can actually reach a viable solution. Completely unfazed by the broader market conditions, some news is making waves in the life sciences sector, driving price movements here and there. It is good to shift the focus away from daily market fluctuations and toward other profitable sectors. Here are a few ideas.
Read
Commented by Armin Schulz on March 20th, 2026 | 08:35 CET
Act Now! Invest in cancer research with BioNTech, Vidac Pharma, and Pfizer and secure returns
Global healthcare spending is surging, and the oncology sector promises above-average returns. As the global population continues to age, the number of new cancer cases is expected to rise to over 30 million annually by 2040, intensifying competition among pharmaceutical companies for market share in this trillion-dollar industry. However, it is not yesterday's established drugs that offer the greatest profit potential, but rather radical technological shifts. While BioNTech is now deploying its billion-dollar mRNA platform against tumors, Vidac Pharma is pursuing an entirely novel approach aimed at starving cancer cells. At the same time, Pfizer is pushing aggressively into this field. We take a closer look at the current situation of these three companies.
Read
Commented by Fabian Lorenz on March 12th, 2026 | 07:25 CET
Breaking News! Takeover speculation? BioNTech, Evotec, Vidac Pharma
First, the positive news: Vidac Pharma's drug candidate VDA-1102 was recently used in a compassionate treatment case in connection with a girl's third brain surgery. Following the treatment, the patient's condition improved significantly. In addition, the Vidac platform is now being tested beyond oncology. 2026 could mark a potential breakthrough year for the company and its stock. It was a different story this week for BioNTech, whose shares suffered a sharp setback. The rather mixed results for 2025 and the cautious outlook for the current year likely played only a limited role. More troubling for shareholders is likely the impending departure of the founding couple. This raises the question: Could BioNTech become a takeover target? There were also long faces at Evotec this week. The company's restructuring program has failed to convince the market, and the stock has slipped below an important technical support level.
Read
Commented by Nico Popp on March 3rd, 2026 | 07:40 CET
Paradigm shift in oncological dermatology: Vidac Pharma as an innovator, what are Almirall and Biofrontera doing?
Oncological dermatology is on the cusp of a revolution that could fundamentally change our understanding of cancer treatment. Persistence Market Research estimates that the global market for the treatment of actinic keratosis will reach a volume of around USD 7 billion by 2026. Analysts expect the market to grow to between USD 11.1 and 14.45 billion by the mid-2030s. This momentum is driven by the aging global population, cumulative UV exposure due to changing leisure habits, and increased awareness of the dangers of skin cancer. Currently, established industry giants such as Almirall and Biofrontera dominate the standard of care for actinic keratosis with their proven products. However, Vidac Pharma marks the transition from merely combating symptoms to a revolutionary procedure in oncological dermatology. This makes the company an opportunity for growth-oriented investors seeking access to a completely new class of drugs in the field of metabolic oncology.
Read
Commented by Mario Hose on February 27th, 2026 | 07:05 CET
Revolution in cancer therapy: Vidac Pharma attacks the cancer throne of the big players! Why the smaller competitor could steal the show from giants like Bayer and BioNTech!
The world of biotechnology and pharmaceuticals is currently in turmoil, as technological breakthroughs and strategic realignments promise an exciting future for investors. The focus is particularly on Vidac Pharma, an innovative company that wants to revolutionize the fight against cancer with a completely new approach to oncology and is currently celebrating one milestone after another. While Vidac Pharma shines with impressive clinical progress and strong internal backing from its main shareholder, Dr. Max Herzberg, industry giant Bayer has recently struggled with the late effects of the Monsanto acquisition, but is now increasingly being touted as an exciting candidate for a split or takeover by financial investors. At the same time, BioNTech remains synonymous with cutting-edge mRNA technology, with the market eagerly awaiting the next phase after the pandemic. In this dynamic environment, Vidac Pharma is emerging as a particularly bright star in the biopharmaceutical sky, causing a sensation with its unique method of specifically normalizing the metabolism of cancer cells.
Read
Commented by Armin Schulz on February 17th, 2026 | 08:10 CET
Cancer Research as a Growth Driver: How Bayer, Vidac Pharma, and Pfizer can enrich your portfolio
Oncology will be put to the test for the pharmaceutical industry in 2026. Never before have so many highly specialized active ingredients been on the verge of market launch at the same time. While checkpoint inhibitors and targeted therapies are revolutionizing treatment, business models are shifting from broad-based approaches to precision medicine. But the reality remains complex: between medical advances, narrow patient groups, and pressure on prices, companies need to readjust. Current developments at Bayer, Vidac Pharma, and Pfizer show how three players with different strategies are responding to this change.
Read
Commented by Fabian Lorenz on February 10th, 2026 | 11:20 CET
SHARE PRICE FIREWORKS! RENK and Novo Nordisk shares take off! Vidac Pharma next?
Share price fireworks at Novo Nordisk yesterday. The battered pharmaceutical stock rose by around 6%. After a weak outlook and the prospect of increasing competition for its blockbuster product, there was some positive news for a change: a competing product is not permitted to be sold in the key US market. RENK shares also rose significantly yesterday. Since last Thursday, the share price has risen by over 10%. Positive analyst commentary is increasing. Vidac Pharma is poised for a rally. The biotech company is working on an attractive oncology pipeline, has once again secured an important patent, and the stock is receiving tailwinds from its Xetra listing. Analysts see the potential for a multiplication.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Nico Popp on January 30th, 2026 | 07:25 CET
The hunt for the cancer pill from BioNTech & Co.: Why Eli Lilly's billion-dollar bet is a wake-up call for Vidac Pharma
It is one of the oldest rules in the biotech sector: when the big pharmaceutical companies can no longer grow on their own, they open their coffers. The latest billion-dollar deal between US giant Eli Lilly and Dresden-based startup Seamless Therapeutics is more than just a headline – it is a wake-up call for the entire industry. Eli Lilly, now one of the most valuable companies in the world, is desperately seeking innovations to secure its pipeline beyond its booming weight-loss injections. This hunger for new mechanisms of action inevitably focuses attention on small, specialized companies researching revolutionary approaches. In this environment, Vidac Pharma is becoming the focus of strategic investors. The Company is working on an approach that is as elegant as it is radical: it aims to starve cancer rather than poison it by manipulating its metabolism. While Eli Lilly and BioNTech are spreading their billions across a wide range of areas, Vidac is delivering precisely the kind of specialized "deep science" that is often lacking in the pipelines of the big players.
Read
Commented by André Will-Laudien on January 19th, 2026 | 07:20 CET
Black Monday: Despite Greenland disputes, tariffs, and Mercosur, biotech is on the rise! Bayer, Vidac Pharma, BioNTech, and Novo Nordisk in focus
The stock market has had a very volatile start to 2026. Now, due to the unresolved Greenland issue, punitive tariffs are even being reintroduced for European countries that wish to stick with the Danish administration. Questions of international law did not impact the stock market in any of the conflicts of 2025. What usually receives a lot of attention, however, are shrinking margins caused by artificial tariffs. Just as the EU had been patting itself on the back over the Mercosur agreement, the next Trump-style threat is looming. The biotech sector is advancing steadily and with considerable momentum. Can the life sciences leaders outperform the DAX?
Read